Frankfurt and London: Why the Cannabis Health Symposium 2026 Matters

The medical cannabis sector is entering a period where progress will depend less on simply making the case for cannabis-based medicines and more on how effectively evidence, clinical practice, regulation and patient experience can be brought together.

That makes the locations chosen for the Cannabis Health Symposium 2026 particularly significant.

Taking place in Frankfurt on 4 November and London on 26 November, the two events sit within very different medical cannabis environments. Together, however, they create an opportunity to examine two of Europe’s most important markets at a point when both are asking increasingly sophisticated questions about access, prescribing, governance and evidence.

Frankfurt: a market in transition

Germany has become one of the most closely watched medical cannabis markets in Europe.

The reforms introduced under CanG have changed the environment in which medical cannabis operates, while prescribing pathways, patient access and the wider regulatory framework continue to develop. The Frankfurt Symposium has therefore been positioned around the practical consequences of that change, rather than simply the legislation itself.

This is strategically important.

A regulatory change can open a door, but it does not automatically create an effective healthcare system. Clinicians still need confidence in prescribing. Pharmacists need clear governance. Patients need reliable pathways into treatment. Regulators require evidence and oversight, while businesses operating within the sector need to understand where commercial activity intersects with healthcare responsibilities.

The Frankfurt programme reflects that complexity. Subjects include the latest clinical evidence, the impact of CanG, prescribing guidance and clinical best practice, patient experience, emerging research and practical insights from professionals working across Germany and Europe.

Frankfurt is also an appropriate setting for those discussions. As one of Germany’s principal business and transport centres, it provides a natural meeting point for German and international participants. Medical cannabis is increasingly a cross-border sector, involving cultivation, manufacturing, distribution, research, investment and healthcare systems that rarely operate within a single national silo.

Bringing those perspectives together in Germany creates an opportunity to examine not simply whether access is expanding, but how that expansion can be supported responsibly.

London: the next stage of the UK conversation

London presents a different strategic challenge.

The UK has had a legal framework for prescribing cannabis-based medicines since 2018, but legal availability has not removed the wider questions surrounding awareness, clinical confidence, patient access, evidence, regulation and the relationship between private prescribing and mainstream healthcare.

The London Symposium therefore provides an opportunity to move the discussion beyond the question of whether medical cannabis has a role in healthcare and towards the more demanding question of how that role should develop.

Its programme is expected to address clinical evidence across a range of conditions, UK policy and regulatory developments affecting access, prescribing guidance and governance, patient perspectives, emerging research and practical experience from clinicians already working within medical cannabis.

London matters because many of the organisations and professions capable of influencing the next stage of UK medical cannabis policy and practice operate there or have strong links to the capital. Bringing clinicians, researchers, policymakers, regulators, patient organisations and responsible industry professionals into the same environment creates space for conversations that are difficult to replicate within individual professional or commercial silos.

For the CTA, that interaction is particularly important. Good policy is rarely created by one part of a sector speaking only to itself.

Two markets, different questions

The value of holding these symposiums in both Frankfurt and London is precisely that Germany and the UK are not following identical paths.

Germany provides an opportunity to examine what happens when significant regulatory change begins to reshape a market. The UK provides an opportunity to consider how an established legal framework can mature, where barriers remain and what must change if patient access and professional confidence are to develop further.

That difference makes comparison useful.

What can the UK learn from Germany’s changing approach? What can Germany learn from several years of UK prescribing experience? Where are clinicians encountering similar challenges? How are patients experiencing access in each system? And where could greater European cooperation in research, education, standards and professional practice make a meaningful difference?

Those are questions that matter well beyond two individual conferences.

Creating the right rooms for difficult conversations

There is also a wider strategic value in the symposium format itself.

The programme combines keynote presentations, expert panels and audience Q&A, deliberately creating opportunities for discussion rather than one-way communication. The organisers identify doctors, specialist clinicians, GPs, pharmacists, nurses, allied healthcare professionals, researchers, academics, policymakers, regulators, patient organisations and responsible industry professionals among the audiences for the events.

That breadth matters.

The future of medical cannabis will not be determined exclusively by legislation, clinical trials, commercial growth or patient demand. It will be shaped by how all of those forces interact.

Frankfurt and London therefore represent more than two dates on the industry calendar. They are opportunities to test assumptions, exchange evidence, compare systems and bring people who influence patient care into the same conversation.

For a European medical cannabis sector that is becoming larger, more visible and more complex, those conversations are becoming increasingly important.